Sunitinib Malate for Gastrointestinal Stromal Tumour (GIST) in Imatinib Mesylate Resistant Patients

Patient Population

Adult patients with unresectable or metastatic/recurrent GIST who have been previously treated with, and subsequently developed resistance or intolerance to IM.

Intended Guideline Users

Clinicians directly involved in the treatment of the target population.

Research Question(s)

Is sunitinib malate (marketed as Sutent) superior to placebo or other intervention for primary outcomes of interest in adult patients with gastrointestinal stromal tumour(s) who have developed resistance or exhibit intolerance to imatinib mesylate?